Comparing tailored vs. standard treatment for active Takayasu's arteritis.
Treatments studied
Part of Heart & circulation, Skin clinical trials.
This trial compares a personalized treatment plan based on your specific disease markers to standard care, aiming to find which is more effective and safer for active Takayasu's arteritis. It may help researchers learn how to better control inflammation and prevent flares.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with active Takayasu's arteritis (NIH score of 2 or more).
- If you are female, you must have a negative pregnancy test and agree not to become pregnant during the trial.
- If you are taking steroids (prednisone or similar), your dose is stable and no more than 0.6 mg per kg of body weight per day.
- You are willing to stop any other arthritis medications for a specific period before starting the trial, as directed.
- You do not have active infections like hepatitis B, active tuberculosis, or cancer.
- You do not have severe organ failure or other autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two medicines—tofacitinib and methotrexate—to see which works better for controlling active Takayasu’s arteritis. It also looks at safety in people with this condition who need treatment right now.
This trial studies treatment options for people age 14 and older with severe, active Takayasu arteritis causing major circulation problems and organ strain. It may help reduce inflammation and complications when the disease is flaring and difficult to control.
This study looks at whether it is safe for people with Takayasu arteritis to stop taking their biologic medication (like TNF inhibitors or tocilizumab) if they have been in remission—meaning their disease has been quiet—for a long time. You might join this trial if your condition has been stable for years and you haven't needed steroids lately.
This trial tests a drug called secukinumab to see if it can help people with severe Takayasu arteritis, a rare disease that causes inflammation in the blood vessels. The drug works by blocking a protein that drives inflammation, which may reduce disease activity and help people lower their steroid dose.
This trial tests whether adding pirfenidone (a drug that reduces scarring) to your usual treatment helps limit blood vessel thickening and scarring in Takayasu arteritis. You must still have some signs of active disease despite being on standard therapy.
This trial is testing two new medications, vunakizumab and ivarmacitinib, to see if they are safe and effective at controlling active Takayasu's arteritis. These medicines work differently from your current treatment, so they might help reduce inflammation and prevent more damage to your blood vessels.
Hear when a new Takayasu Arteritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.